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Abstract: Prostate cancer (PCa) is the second most diagnosed cancer in men worldwide. For its
screening, serum prostate specific antigen (PSA) test has been largely performed over the past
decade, despite its lack of accuracy and inability to distinguish indolent from aggressive disease.
Metabolomics has been widely applied in cancer biomarker discovery due to the well-known
metabolic reprogramming characteristic of cancer cells. Most of the metabolomic studies have
reported alterations in urine of PCa patients due its noninvasive collection, but the analysis of prostate
tissue metabolome is an ideal approach to disclose specific modifications in PCa development. This
review aims to summarize and discuss the most recent findings from tissue and urine metabolomic
studies applied to PCa biomarker discovery. Eighteen metabolites were found consistently altered
in PCa tissue among different studies, including alanine, arginine, uracil, glutamate, fumarate, and
citrate. Urine metabolomic studies also showed consistency in the dysregulation of 15 metabolites
and, interestingly, alterations in the levels of valine, taurine, leucine and citrate were found in
common between urine and tissue studies. These findings unveil that the impact of PCa development
in human metabolome may offer a promising strategy to find novel biomarkers for PCa diagnosis.
Keywords: metabolomics; volatilomics; lipidomics; prostate cancer; urine; tissue; biomarkers;
metabolic pathways
1. Introduction
Cancer diseases are one of the most important health problems worldwide, prostate
cancer (PCa) being one of the most prevalent. Indeed, PCa is globally the second most
frequently diagnosed male malignancy and the fifth leading cause of cancer, with more than
1,000,000 new cases and more than 350,000 deaths, each year [1]. PCa is a heterogeneous
disease [2] with a broad spectrum of aggressiveness, going from indolent PCa, which is a
non-life-threatening cancer, to metastatic PCa with a 5-year survival of 28% [3].
Currently, PCa screening is based in serum prostate specific antigen (PSA) test and
digital rectal examination (DRE) [4], whereas prostate biopsy (PB) is mandatory for a
final diagnosis [5]. High levels of PSA (>4 ng/mL) are considered a sign of PCa [4].
However, this biomarker shows important limitations [6], due to its reduced accuracy
(accu) (62–75%) [7], sensitivity (sens) (20.5%), specificity (spec) (ranging from 51% to
91%) [4,8], and area under the curve (AUC) (varying from 0.53 to 0.83) [7]. These low
performance values can be due to interference from other diseases, like benign prostate
hyperplasia (BPH) or prostatitis, that may also lead to an increase in serum PSA levels [2,6].
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Furthermore, PSA testing is unable to distinguish indolent from aggressive disease, leading
to unnecessary PB [2]. As matter of fact, about 70% of the PB performed due to high levels
of PSA do not detect PCa and could be avoided with a more accurate PCa screening test [6].
PB is an invasive procedure that is associated to several adverse effects, like hemoejaculate,
hematuria, fever, pain, and hematochezia. Although more rare, other complications, like
bleeding, acute urinary retention, local infection, sepsis, vasovagal syncope, and erectile
dysfunction, can also occur as a consequence of PB [9]. Moreover, PB can fail to diagnose
over 30% of clinically significant PCa (non-indolent). On the other hand, PB can also lead
to overdiagnosis and overtreatment of indolent PCa, that will not bring advantages to the
patients′ health and can negatively affect patients′ quality of life [5].
PCa can be curable if diagnosed when the development is still in its early stages [3].
For localized PCa, the gold standard treatment is radical prostatectomy (RP). However,
around 40% of the patients will develop biochemical recurrence (BCR) after RP, which
indicates PCa progression [10]. After RP, levels of PSA decrease until undetectable, and
the resurgence of high PSA levels is the first indication of BCR. The ideal PSA cut-off to
define BCR is still controversial [10], with the American Urological Association and the
European Association of Urology defining BCR for a serum PSA ≥ 0.2 ng/mL [10,11].
For aggressive PCa, one of the most frequently used treatments is androgen deprivation
therapy (castration). However, the treatment can be hampered by the development of
resistance to castration [12].
Considering the limitations of the currently available PCa diagnostic tools, the sci-
entific community has performed massive efforts to discover new biomarkers for PCa
detection. These biomarkers include several derivatives of PSA, like the prostate health
index (PHI) and the 4Kscore tests. PHI test combines the PSA precursor isoform that
circulates uncomplexed [−2]proPSA (p2PSA), free PSA (fPSA) and total PSA, through
the formula PHI = (p2PSA/fPSA) ×
√
(tPSA) [13,14]. Higher levels of PHI are correlated
with PCa [13,14] and this test obtained FDA approval for men with PSA between 2.5 and
10 ng/mL and negative DRE [2]. The 4Kscore test includes total PSA, fPSA, intact PSA
(iPSA), and human glandular kallikrein (hK2), a protein similar to PSA [2]. Despite the
promising results, 4Kscore test did not obtain FDA approval [2].
With the raising of “omics” technologies, other biomarkers for PCa detection have
been proposed, such as prostate cancer antigen 3 (PCA3), which is a biomarker coming from
transcriptomic methodologies. PCA3 gene encodes a noncoding RNA which is specific
of prostate and is increased in urine of PCa patients collected after DRE. Despite the
controversy around the ideal cut-off for the levels of this biomarker, this test obtained FDA
approval for men with high PSA levels and/or positive DRE and/or previous negative
PB [15,16]. Prostarix test, which is also performed in urine after DRE, was developed using
metabolomic approaches and detects four amino acids [17], namely sarcosine, glycine,
alanine, and glutamate [13,16]. This test has not yet obtained FDA approval [13], but it is
commercially available and is recommended for men with persistent PSA increase and
previously negative PB [13,17].
Despite such great efforts to discover new biomarkers for PCa detection and the
promising perspectives, no biomarker has so far been able to replace PSA in clinical
practice for PCa screening, highlighting the need to pursue research in this field. In this
review, we explore the potentialities and challenges of metabolomics for PCa biomarker
discovery. In addition, we update our earlier review [18] by presenting the most recent
metabolomic studies performed in urine and tissues from PCa patients aimed at evaluating
metabolic pathways perturbed in this disease and the altered metabolites as potential
biomarkers for PCa detection. For this, a search was conducted in the PubMed database
for articles published between January of 2015 and December 2020, using the keywords
“metabolomics”, “prostate cancer”, “biomarker”, “urine”, or “tissue”. A total of 25 studies
were included, of which 12 were performed in PCa tissue samples, 12 in PCa urine samples
and one study included both matrices.
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2. Metabolomic Approaches to Biomarker Discovery
Nicholson et al. (1999) defined metabonomics as “the quantitative measurement of
the dynamic multiparametric metabolic response of living systems to pathophysiological
stimuli or genetic modification” [19]. Nowadays, the term metabonomics is often used
interchangeably with the terms metabolic phenotyping, metabolic profiling, or simply
metabolomics in the context of the comprehensive analysis of all metabolites of a biological
sample representative of an organism or cell. Metabolomics is the last “omic” platform
in the “omics” cascade (genomics—transcriptomics—proteomics—metabolomics), and it
focuses on the study of small molecules (<1500 Da) [20] in several complex matrices like
serum, saliva, exhaled air, urine, tissue, among others [21]. When compared with other
omics, metabolomics shows important advantages: (i) the dynamic feature of metabolome,
once it modifies rapidly in response to changes in cell status, allowing a continuous evalu-
ation of the cell state [22]; (ii) minor changes in gene expression or protein synthesis are
translated into major alterations in metabolite levels [23]; (iii) the response of metabolome
to pathophysiological alterations is much more sensitive than gene or protein response [24];
(iv) the alterations in metabolome are closely related with the observed phenotype; (v) the
levels of several metabolites can simultaneously be measured, allowing to establish a
pattern of alterations associated with an specific pathophysiological state [22]; (vi) allows
to define patterns of disease progression [25].
Human metabolome comprises metabolites of low molecular weight from very differ-
ent chemical families, such as amino acids, lipids, nucleotides, carbohydrates, organic acids,
among others. They are present in a wide range of concentrations and have distinct physic-
ochemical characteristics [26]. When a metabolomics study is designed, the selection of the
analytical technique is a critical step, once this choice will restrict the metabolites detected
and consequently the obtained results [27]. This selection needs to take into consideration
the characteristics of the analytical technique like sensitivity, resolution, limits of detection
of the instrumental technique [27], but also the characteristics of the samples and of the
metabolites of interest, e.g., metabolite physicochemical properties and abundance [27,28].
Currently, the majority of the metabolic studies are performed using mass spectrome-
try (MS), frequently coupled with a separation technique like gas or liquid chromatography
(GC–MS or LC–MS), and nuclear magnetic resonance spectroscopy (NMR) [26,29]. MS and
NMR show several differences, including in the detected range of concentrations, namely,
MS allows the detection of metabolites in concentrations ranging from picomolar (pM) to
millimolar (mM) [30] and NMR from micromolar (µM) to millimolar (mM) [31]. Table 1
summarizes the advantages and limitations of the three analytical techniques (GC–MS, LC–
MS and NMR), for metabolomic studies. As depicted in Table 1, none of these methods are
able to cover the entire metabolome. For example, GC–MS is only suitable for the analysis
of thermally stable compounds, such as volatile organic compounds (VOCs) [26]. In turn,
LC–MS is used for profiling of compounds with medium and low polarities (reversed-
phase LC) and polar compounds (hydrophilic-interaction LC), but the datasets generated
are complex, spectrometer dependent, and require additional MS/MS experiments, as well
as spiking with authentic standards, in order to perform metabolite annotation and identi-
fication [26,32,33]. NMR shows a lower sensitivity, which compromise the detection of low
abundance metabolites. Importantly, due to NMR nondestructive nature, the samples can
be recovered after analysis and used in complementary studies (e.g., MS analysis) to obtain
a more comprehensive characterization of the metabolome [34]. Indeed, the combination
of more than one analytical platform is desirable to allow a more comprehensive analysis
of a sample metabolome [26,29].
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Table 1. Main advantages and limitations of gas or liquid chromatography coupled with mass spectrometry (GC–MS or
LC–MS), and nuclear magnetic resonance spectroscopy (NMR) in metabolomic studies.
Analytical Platform Advantages Limitations
GC–MS
- Ideal for volatile organic compounds detection [26]
- High sensitivity and resolution [26]
- Available database for metabolite
identification [26]
- High peak capacity to cover a wide range of
concentrations [22]
- Small amounts of sample used [32]
- High dynamic range, selectivity and
throughput [26,29,35]
- Retention times are highly reproducible [22,26]
- Only suitable for thermally stable
compounds [26]
- Derivatization step is required for
nonvolatile compounds [26]
- Formation of new compounds due
the derivatization step [28]
- Destructive nature [32]
LC–MS
- Detects a wide range of metabolites, including
conjugates, of varying molecular weight and
different natures (hydrophilic and hydrophobic
compounds) [22,26]
- Easy sample preparation [26,28]
- Does not require derivatization [22]
- Small amounts of sample used [32]
- Destructive nature [32]
- MS/MS experiments are usually
required for metabolite
identification, which implies
additional experimental time [33]
NMR
- Relatively high throughput and efficiency [22,36]
- High reproducibility and selectivity [34,37]
- Nondestructive nature [22,34]
- Analysis of liquid and solid matrices [34]
- Easy sample preparation [37]
- Provides information about chemical structure,
chemical environment and molecular
interactions [34,36]
- Low sensitivity [34,37]
- High costs [22]
- Not optimal for targeted
analysis [37]
- Peak overlapping which difficult
quantification [34]
Metabolomic studies can follow two distinct approaches, namely the untargeted or
the targeted approach. In the first, the goal is to cover the maximum of the metabolome
detecting as many metabolites as possible in a matrix, and is frequently denominated
as hypothesis generation [23]. In the second, a single metabolite or a group of metabo-
lites (e.g., metabolites from a specific metabolic pathway) are previously selected and
all the study is designed to detect and quantify these metabolites. This approach can be
applied to validate the results obtained through an untargeted approach and is called
hypothesis-driven [23,25].
Regarding PCa metabolomic studies, two main goals are recognized: (i) the discovery
of biomarkers with high sensitivity and specificity for PCa timely detection and (ii) to un-
derstand the metabolic basis of PCa pathogenesis identifying altered metabolic pathways
in consequence of PCa development and progression [25]. Nevertheless, the potential ap-
plication of metabolomic studies is not limited to these two main goals, once metabolomic
studies can also be applied to study the effectiveness of treatments, as well as the mecha-
nism of action of therapeutic drugs and the mechanism of drug resistance or contribute to
achieve the goal of personalized medicine [38].
Over the years, several independent subareas emerged from metabolomics, like
volatilomics, lipidomics, among others. Volatilomics is based on the analysis of VOCs,
like aldehydes, ketones, alcohols, hydrocarbons, or aromatic compounds [39], that are pro-
duced by human body and released into breath, blood, sweat, urine, feces, or saliva [39,40].
All VOCs share some physicochemical characteristics, such as low molecular weight and
low boiling point and/or elevate vapor pressure in normal conditions [41]. The interest to
investigate VOCs as potential cancer biomarkers gained strength after the observation that
dogs were able to “smell” urine or skin samples of cancer patients with high sensitivity
and specificity, indicating that the composition of VOCs is different in cancer individu-
als [42–44]. VOCs are end products of human biological activity and their composition in
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biological samples can reflect pathological processes [40], alterations in normal biochemical
pathways and/or a response to a damage or disease. Indeed, cancer development and
progression can lead to the production of new VOCs and/or to change their concentra-
tion [41], making them suitable candidates to cancer biomarkers [39]. One of the greatest
advantages of VOCs as biomarkers is the possibility to easily, inexpensively and quickly
detect them in clinical point of care through the most recent technological developments in
biological sensors (e.g., electronic noses (e-nose)) [39].
Lipidomics is the subarea of metabolomics focused on the qualitative and quantitative
profile of the lipid species in biological samples [45]. The knowledge of lipid metabolism is
crucial to understand cancer development and progression for several reasons: (i) de novo
synthesis provide phospholipids for cancer cell proliferation, (ii) fatty acid β-oxidation
is important in energetics and redox homeostasis, (iii) lipids play an important role in
signaling pathways [46] and, finally, (iv) lipids are extremely dynamic and can reflect phys-
iological, pathological, and environmental alterations [47]. For these reasons, the interest
to study the lipid profile of cancer cells has increased in the last years. It is estimated
that mammalian cells comprise around 10,000 individual lipid species [48]. These lipids
can be classified into different classes: (i) fatty acids, (ii) glycerophospholipids (GPLs),
(iii) glycerolipids (e.g., triglycerides (TG)), (iv) saccharolipids, (v) sphingolipids (SL), and
(vi) sterols. Each class of lipids show different biological functions. For instance, TG are
important for energy storage, while sterols are key elements in cellular membrane and
have also hormonal functions [49]. GPLs and SL are important components of cellular
membranes and lysophospholipids (LPLs) (a subclass of GPLs) are important molecules
for cellular signaling. These three classes (GPLs, SL and LPLs) are the most frequently
studied in cancer lipidomic studies. GPLs can still be divided into phosphatidylcholine,
phosphatidylethanolamine (major components of human cellular membranes), phospha-
tidic acid, phosphatidylglycerol, phosphatidylinositol and phosphatidylserine, considering
the molecular structure of these molecules. SLs can also be divided into several subclasses
like ceramides, sphingomyelins, among others [45]. This summary reflects the importance
and the complexity of the lipidome and justify that lipidomics comprises an independent
subarea of metabolomics. Furthermore, several studies revealed that cancer cells show
alterations in lipidome fingerprint demonstrating the potential of lipids as biomarkers
and/or therapeutic targets [46,49].
3. The Metabolic Phenotype of Prostate Cancer
It is well established that cancer cells suffer profound metabolic alterations that are
indispensable for cancer development and progression [50]. One of the most well described
metabolic alterations of cancer cells is the Warburg effect, which is characterized by a
change in the preferential pathway to produce energy. Indeed, cancer cells preferentially
produce ATP via aerobic glycolysis, even in the presence of oxygen, while normal cells
produce ATP through oxidative phosphorylation [50,51]. This shift leads to an increase
in glucose uptake and in lactate secretion [50,52]. The increase in lactate levels seems to
play an important role in cancer development and progression [50]. Lactate can be utilized
as fuel for oxidative metabolism, metabolized into alanine and glutamine and can also
intervene in cancer cell mobility, immune escape and angiogenesis [50].
To comprehend how the Warburg effect impacts PCa cell metabolism, it is important
to revisit the peculiar metabolic phenotype of normal prostate cells. Contrarily to other
human cells, prostate cells favor citrate accumulation instead of citrate oxidation for energy
production through tricarboxylic (TCA) cycle, also known as Krebs cycle or citric acid
cycle [53]. Prostate cells have an increase in the zinc transporter ZIP1 and, consequently,
zinc accumulates in prostate tissue [52]. The high levels of zinc are responsible for the
inhibition of m-aconitase, which is the enzyme responsible for citrate oxidation in TCA
cycle [53]. However, one of the first metabolic alterations associated with PCa development
is the loss of cell ability to accumulate zinc and subsequent reduction of citrate levels in
PCa cells [53]. Indeed, there is an increment of citrate oxidation in TCA cycle to produce
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energy in PCa cells [52,53]. For this reason, the Warburg effect and consequent increase in
aerobic glycolysis is described mainly in advanced stages of PCa, where the increase in
glycolytic pathway is associated with metastases formation and thereafter to a poor progno-
sis [52,54]. Furthermore, citrate can also be used in PCa cells to produce acetyl-coenzyme A
(acetyl-CoA) (important for fatty acids and cholesterol synthesis) and oxaloacetate (amino
acid precursor) [55] (Figure 1). Beyond citrate accumulation, normal prostate cells can
also accumulate polyamines, such as spermine and spermidine once they are important
components of prostatic secretions [56]. Polyamine levels also decrease, similarly to citrate,
during cancer development and progression (Figure 1). Indeed, this reduction in polyamine
levels may promote PCa cell survival by preventing apoptosis [55,56].
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Underline indicates changes especially important in advanced PCa. The dashed lines represent multiple steps reactions.
(α-KG, alpha-ketoglutarate; Ac-CoA, acetyl-coenzyme A; Chol, choline; G6P, glucose-6-phosphate; GNMT, glycine N-
methyltransferase; Isocit, isocitrate; Met, methionine; NO, nitric oxide; OAA, oxaloacetate; PCs, phosphatidylcholines; PEs,
phosphatidylethanolamines; PPP, pentose phosphate pathway; R5P, ribose-5-phosphate; SAH, S-adenosylhomocysteine;
SAM, S-adenosylmethionine; SARDH, sarcosine dehydrogenase; TCA cycle, tricarboxylic acid cycle).
Pentose phosphate pathway (PPP) is also altered in PCa cells, once the levels of
glucose-6-phosphate dehydrogenase (a key enzyme in PPP) are increased through androgen
receptor (AR) signaling [54], which is essential for PCa progression. AR signaling also
promotes glycolysis and anabolism [55]. As previously referred, one of the most frequently
used treatments for aggressive PCa is androgen deprivation therapy, which is associated
to the development of castration-resistant state and consequently alterations in the lipid
profile, and to a worse prognosis [55,57]. Furthermore, PCa cells show the ability to
synthesize sterols, highlighting the importance of androgen signaling in PCa [57] (Figure 1).
Alterations in different amino acids, such as glutamine, have been associated with
PCa and other cancers [50,52]. Glutamine is one of the most abundant amino acids in
human plasma and has important roles in human metabolism [54], as it can be converted
in glutamate, and subsequently be transformed in α-ketoglutarate, an intermediate in TCA
cycle [50,52]. This amino acid can also be used by cancer cells for acetyl-CoA produc-
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tion [54], for fatty acid synthesis [52] and as a nitrogen and carbon donor for nucleotide,
lipids and protein synthesis [50,54]. The glutamate resulting from glutamine is an essential
substrate for glutathione synthesis, and therefore important for the protection of the cells
against oxidative damage [50] (Figure 1). Arginine is an important amino acid involved
in PCa metabolism. Arginine is converted by PCa cells in glutamine and/or proline [52].
The increase in proline levels is needed to the maintenance of the levels of pyridine nu-
cleotides [54]. Arginine has also an important role in nitric oxide (NO) production [52]
(Figure 1).
Sreekumar et al. (2009), reported higher levels of sarcosine in urine of PCa patients,
which was a milestone in PCa metabolomics [58], but its importance as potential PCa
biomarker was refuted in the following years [59–61]. Sarcosine is synthesized from other
amino acids, glycine, and vice versa. This reaction can be linked to methionine cycle,
and the produced methionine can be up-taken to folate cycle. The combination of these
two cycles is referred frequently as one-carbon metabolism. One-carbon metabolism
fuels building blocks for purines and thymidylates synthesis, which are essential for
DNA synthesis and repair [62,63]. Methionine cycle also plays a role in polyamines and
glutathione synthesis [54,63] (Figure 1).
Another prominent characteristic of a cancer cell is its ability to proliferate constantly.
Lipids are major components of cellular membranes, so alterations in lipids, and in choline
or choline derivative metabolites, have a very important role in cancer cells prolifera-
tion [53,54]. Furthermore, lipids are also essential as energy resource, for energy storage
and for intracellular signaling [54]. Therefore, increase in de novo fatty acids synthesis is an
initial event in PCa development, which is stimulated by androgen signaling [52], as well
as the increase in fatty acids oxidation to produce energy [52,54]. The importance of lipoge-
nesis in PCa is patent in the increase of the expression of lipogenic and lipid-modifying
enzymes, occurring in PCa [52,54] and by the accumulation of triglycerides, cholesterol
esters and phospholipids (phosphatidylcholine), mainly in aggressive PCa [53]. Further-
more, metastatic PCa cells also show an upregulation of acetyl-CoA synthetase 2, allowing
PCa cells to produce acetyl-CoA (essential for fatty acids synthesis) from acetate, while
normal cells produce acetyl-CoA essentially from glucose and glutamine [54] (Figure 1).
Moreover, PCa cells show the ability to take up exogenous lipids and to synthetize and
mobilize lipids storage in other cells, like adipocytes [54].
From this brief explanation, it is reasonable to infer that the study of the metabolic
signature of cancer cells has an enormous potential in the discovery of new biomarkers, as
well as to elucidate cancer pathophysiological mechanisms, which can be used to define
new therapeutic strategies.
4. Tissue Metabolomic Studies
The collection of tissue samples is very invasive, hampering their use for PCa scree-
ning. However, the study of the tissue metabolome has important advantages, once this is
the ideal matrix to establish which metabolic alterations are specific to PCa development
and progression. Furthermore, tissue studies have been performed using matched tumoral
and nontumoral samples from the same individual, thus minimizing the contribution of
confounding factors (e.g., age, comorbidities, lifestyle).
Thirteen metabolomic studies performed in PCa tissue samples were published in
the last 5 years, including two lipidomic studies. Table 2 summarizes the study design
and main outcomes obtained in those studies. Overall, a total of 98 different metabolites
were associated with PCa, indicating that PCa is related with dysregulations in 32 different
metabolic pathways (Table 2). Interestingly, 18 metabolites were found to be common
among the included studies (Figure 2). It is important to note that these studies were per-
formed under different analytical conditions, with different sample selection criteria and
using different statistical approaches, foreseeing difficulties to compare results across stud-
ies. The fact that these metabolites were found common in the various studies, highlights
their importance in PCa metabolism and their potential as specific PCa biomarkers.
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Table 2. Metabolomic studies performed in tissue samples from PCa patients in the last 5 years (2015–2020).
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15. Lysine (+); Threonine (+)
Notes: (+) indicates increased levels in PCa, (−) indicates decreased levels in PCa; the numbering of the column Altered Metabolites is related with the numbering of the column Dysregulated metabolic
pathways. Abbreviations: 1H-NMR, proton nuclear magnetic resonance spectroscopy; 31P NMR, phosphorus-31 nuclear magnetic resonance spectroscopy; accu, accuracy; AUC, area under the curve; BPH,
benign prostatic hyperplasia; CE–MS, capillary electrophoresis–mass spectrometry; CEs, cholesteryl esters; PCs, ether-linked phosphatidylcholines; ESI–MS, electrospray ionization–mass spectrometry;
ERG, ETS-related gene; FAs, fatty acids; GC-FID, gas chromatography-flame ionization detector; GC–MS, gas chromatography–mass spectrometry; GS, Gleason score; HR-MALDI-IMS, high-resolution
matrix-assisted laser desorption/ionization imaging mass spectrometry; HR-MAS 1H-NMR, high resolution magic angle spinning proton nuclear magnetic resonance; LC–MS, liquid chromatography–mass
spectrometry; LPC, lysophosphatidylcholine; OPLS-DA, orthogonal projections to latent structures discriminant analysis; OSC-PLS-DA, orthogonal signal corrected partial least squares-discriminant analysis;
PCA, principal component analysis; PEs, phosphatidylethanolamines; PLS-DA, partial least squares-discriminant analysis; sens, sensitivity; spec, specificity; SM, sphingomyelin; TCA, tricarboxylic acid cycle.
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The most frequent alteration reported among the studies conducted in the last 5 years
is the significant decrease in citrate levels in PCa tissue [68,74–76] (Table 2 and Figure 2).
This result is not unexpected as the loss of capability to accumulate citrate is one of the
first metabolic alterations observed in prostate cells during malignant transformation. This
loss of capability to accumulate citrate translates in a profound alteration in energetic
metabolism of PCa cells, once PCa cells start to use citrate in TCA cycle more efficiently
than normal prostate cells [51,52]. Furthermore, Braadland et al. (2017) compared PCa
tissue from men that suffered PCa recurrence after prostatectomy with tissue from men
that, until the date of the study, did not show signals of recurrence, unveiling that lower
levels of citrate in PCa tissue were associated with shorter time of recurrence [70]. Addi-
tionally, lower levels of citrate were also associated with more aggressive PCa [77]. Beyond
citrate, two other metabolites involved in energetic metabolism, namely alanine [69,71]
and lactate [69,72] showed significant alteration in PCa tissue.
The increased levels of other key metabolites of TCA cycle have also been frequently
cited in the reviewed studies, namely succinate [71,76], malate [71,76] and fumarate [71,74,76]
(Table 2, Figure 2). The increase in malate and fumarate levels was also correlated with
Gleason score [71,78] and tumor stage [71]. Notably, both succinate and fumarate were
previously considered oncometabolites [49], once their accumulation leads to cancer pro-
gression [79]. The increased levels of succinate and fumarate have been asso-ciated in
other cancer types (e.g., paraganglioma, pheochromocytoma or kidney cancers [78]) with
mutation in the enzymes succinate dehydrogenase (SDH) and fumarate hydratase (FH),
respectively [49,80]. However, these results were not observed in PCa studies performed
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by Shao et al. (2018), which suggested the involvement of other mechanisms that could also
be related with the increase of the levels of these metabolites in PCa [71]. Once fumarate
is also linked with urea cycle [74,76], this metabolic pathway could be res-ponsible for
keeping the high levels of fumarate in PCa tissue [74,79]. As previously referred, the
accumulation of fumarate leads to cancer progression, this could involve the activation of
hypoxia-inducible factor 1-subunit alfa (HIF1α) and NFκB pathways [74]. HIF1α plays
an important oncogenic role in PCa once this pathway is responsible for many essential
mechanisms to guarantee PCa cell survival, like antiapoptosis, angioge-nesis and increased
glycolytic metabolism. Furthermore, HIF1α protects PCa cells against oxidative stress and
against the cytotoxicity caused by androgen deprivation therapy, chemotherapy, or radia-
tion [81]. Similarly, NFκB pathways support PCa cell survival, proliferation, and invasion,
playing an important role in the development of resistance to castration therapy [82].
The increase in uracil levels is another alteration consistently reported in PCa tissue (Table 2,
Figure 2), suggesting that PCa cells have alterations in pyrimidine metabolism [65,71,76]. Pyrim-
idine metabolism is a complex biochemical pathway that comprises diffe-rent reactions,
namely de novo nucleotide synthesis, nucleoside salvage, and pyrimidines degradation [83].
Pyrimidines, like uracil [84], are essential in cells metabolism once they are constituents
of nucleotides, nucleic acids, vitamins, proteins, and folates [85]. Furthermore, they are
key intermediates in RNA and DNA synthesis, protein and lipids glycosylation, synthesis
of phospholipid precursors [84,85], and in reactions of glucuronidation [84]. Cancer cells
are dependent on de novo nucleotide synthesis for cell proliferation and consequently for
cancer development and progression [83,84]. Importantly, the inhibition of this metabolic
pathway is a strategy adopted in the treatment of several cancers (e.g., colorectal cancer
and pancreatic cancer) [84,86,87].
One of the main functions of normal prostate is to synthesize polyamines like spermine
but apparently this function is impaired with PCa development and progression [70]
leading to a decrease in the levels of spermine [68,76]. Indeed, the reduction of spermine
levels was proposed as a biomarker able to predict BCR [70]. Interestingly, levels of
spermidine, a spermine precursor, were also reported as significantly altered in PCa tissue
samples; however, the obtained results were contradictory. Huan et al. (2016) found a
significant increase in the levels of spermidine [65], whereas Dudka et al. (2020) showed a
significant decrease in the levels of this metabolite in PCa tissue samples [76].
As previously referred, lipid metabolism can be an important source of PCa biomark-
ers, emphasizing the relevance of lipidomic studies. The major reported lipidic alterations
occurring in PCa cells involved phospholipids from cellular membrane [64,66,67,69,71–73,76]
which was expected taking into consideration that cancer cells show a high proliferative
phenotype. Notably, the significant decrease in the levels of LPC (16:0) was able to predict
BCR [64]. This observation is supported by a transcriptomic study, that evaluates the
expression of the enzyme LPC transferase 1 (LPCAT1). The increase in the expression of
this enzyme was able to discriminate PCa from benign tissue, as well as to differentiate PCa
with different GS and to predict BCR and/or metastasis development [88]. Furthermore,
phosphocholine also revealed to be able to discriminate PCa tissue with different GS [76].
Finally, alterations in amino acid metabolism have also been widely reported in PCa,
mainly in the increase levels of glutamate [72,75,76], tyrosine [74,75], arginine [74,76], and
proline [71,74]. Importantly, the significant alteration in the levels of the first three amino
acids was associated with GS and consequently PCa aggressiveness [76], making these
metabolites potential diagnosis and prognosis biomarkers.
5. Urine Metabolomic Studies
Urine is the ideal matrix to be used in a screening test, due to its noninvasive nature,
along with ease of collection and handling, high volume which allow repeated analysis, and
lower complexity when compared with other biofluids (e.g., serum or plasma) [20,37,89].
Furthermore, urinary metabolites are concentrated by the kidneys, which are anatomically
close to the prostate [89,90]. However, urine composition can vary due to several external
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factors, like diet, smoking habits, genetic factors, microbiota, diurnal cycles diabetes, and
other diseases which can affect urine metabolome [91].
From 2015 to 2020, 13 studies performed in PCa urine samples were published, includ-
ing four volatilomics studies. Table 3 summarizes these studies, highlighting study design,
altered metabolites, metabolic pathways, as well as candidate biomarkers, whenever avail-
able. Overall, 179 different metabolites were associated with PCa, indicating that PCa is
correlated with dysregulations in 48 different metabolic pathways. In this section, the
metabolites that hold greatest potential as PCa biomarkers will be highlighted, considering
different selection criteria: (i) consistency among different urinary studies, (ii) AUC greater
than PSA and (iii) translatability between tissue and urine studies.
Despite the great differences (e.g., different analytical platform, samples preparation
or different inclusion/exclusion criteria) among the study designs, 15 metabolites have
been consistently reported with the same variation among different urinary studies, as
represented in Figure 3. Importantly, four metabolites out of the 15 have also been reported
with the same alteration in PCa tissue, namely decreased levels of citrate [68,74–76,92,100],
increased levels of leucine [74,97,102], increased levels of valine [74,97,102], and increased
levels of taurine [96,100,104], suggesting that these alterations may be specific of PCa
tumors and suggesting their translatability between tissue and urine samples (Figure 3).
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acids; GC–MS, gas chromatography–mass spectrometry; GS, Gleason score; HS-SPME, headspace solid-phase microextraction; LC-ESI-MS/MS, liquid chromatography electrospray
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ROC, receiver operating characteristics curve; sens, sensitivity; spec, specificity; TCA, tricarboxylic acid cycle; UPLC-MS/MS, ultra-performance liquid chromatography-tandem mass
spectrometry.
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In addition, 12 metabolites stood out once they unveiled similar or even better per-
formance than PSA (AUC ranging from 0.53 to 0.83) for PCa detection [7], namely γ-
amino-n-butyric acid (AUC: 0.93), phosphoethanolamine (AUC: 0.88), ethanolamine (AUC:
0.86), homocitrulline (AUC: 0.84), asparagine (AUC: 0.773), arginine (AUC: 0.83) [96],
spermine (AUC: 0.83) [94], δ-hydroxylysine (AUC: 0.80) [96], 2-hydroxyvalerate (AUC:
0.76), 2-furoylglycine (AUC: 0.74), mannitol (AUC: 0.69), and glucose (AUC 0.69) [102].
From these 12 metabolites, the alterations observed in the levels of three metabolites were
previously reported in PCa tissues, namely spermine [68,76], ethanolamine [105] and glu-
cose [76]. Importantly, the decrease in glucose levels was also correlated with GS [76].
The significant alterations observed in the other nine metabolites, to the best of our knowl-
edge, were not previously reported in PCa tissue. It is important to highlight that even if it
is not possible to prove translatability of a metabolite from tissue to urine, this does not
invalidate its potential as PCa biomarker once its alteration can for example be driven from
a systemic response to PCa development and progression.
The volatilomic studies have been more focused in the definition of biomarker pan-
els for possible detection through biosensors rather than proposing individual biomark-
ers [93,99,103]. The smallest biomarker panel reported included four metabolites (2,6-
dimethyl-7-octen-2-ol, 3-octanone, 2-octanone and pentanal) [93], which unveiled accura-
cies at least equal to PSA (accu. of 62–75% for PSA vs. accu. of 63–65% for the 4-biomarker
panel [7,93]. Remarkably, a 6-biomarker panel (hexanal, 2,5-dimethylbenzaldehyde, 4-
methylhexan-3-one, dihydroedulan IA, methylglyoxal, 3-phenylpropionaldehyde) [99] and
an improved 10-biomarker panel (methylglyoxal, hexanal, 3-phenylpropionaldehyde, 4-
methylhexan-3-one, 2.5-dimethylbenzaldehyde, dihydroedulan IA, ethylbenzene, heptan-2-
one, heptan-3-one, 4-(2-methylpropoxy)butan-2-one, methyl benzoate, 3-methyl-
benzaldehyde) [103] were recently proposed that outperformed PSA in all performance
parameters (PSA: acc = 62–75%, sens = 20.5%, spec = 51–91% [4,7,8]; 6-biomarker panel:
acc = 86%, sens = 89%, spec = 83% [99]; 10-biomarker panel: acc = 92%, sens = 76%,
spec = 90% [103]). Notably, the 10-biomarker panel proved to be able to differentiate
PCa from cancer-free individuals as well as from other urological cancers (renal and
bladder cancers) [103].
Overall, findings from the reviewed studies showed that PCa development and pro-
gression is mainly associated with alterations in amino acid metabolism, energy metabolism,
especially in TCA cycle, and membrane metabolism (Tables 2 and 3).
6. Current Challenges and Future Perspectives
There are no doubts that the scientific community has made enormous efforts to
define the impact of PCa in human metabolome with dozens of studies focused on this
topic, not only using tissue and urine matrices but also other biological samples as serum,
plasma, seminal fluid, prostatic fluid, and even cell lines [18]. However, some biological
and technical challenges should be addressed before we can translate all the potentialities
of metabolomics into clinical practice.
The traditional paradigm is to find a single biomarker for PCa screening. However,
during the last years, the idea of using a panel of biomarkers instead of a single biomarker
has gained strength, especially in volatilomic studies. The use of a biomarker panel
has important advantages, once a multi-biomarker panel may be able to capture more
deeply the various metabolic dysregulations occurring during cancer development and
progression than a single biomarker [106]. Hence, a multi-biomarker panel allows the
definition of a more robust signature of PCa providing a better evaluation of cancer
progression. Furthermore, the use of a biomarker panel avoids that an arbitrary change in
a single metabolite leads to a false result [22].
As referred in the previous section, the comparison of the findings from different stud-
ies is compromised by the lack of standardized procedures in metabolomic studies, espe-
cially in study design which consequently increases interlaboratory variability [107]. Many
efforts have been made to accomplish the goal of standardized procedures in metabolomics
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studies in the last years [107,108]. There is still a long way to go until the desired standard-
ization, but the first steps have already been taken [108].
Other crucial technical challenge is metabolite identification. This is particularly true
in volatilomics studies. Additionally, the interpretation of the urinary volatilome signature
of PCa is particularly challenging once there is no clear understanding of the biological
origin of VOCs [39]. In addition, the volatilome of PCa tissue has not been explored so
far, to our knowledge, hindering the elucidation of a potential translatability of VOCs
from tissues to urine samples. In future, this issue can be addressed through volatilomics
studies of PCa tissue and fluxomic studies. Fluxomic studies allow the understanding of
the metabolic origin of endogenous VOCs by labeling and tracking metabolic precursors
(e.g., glucose), throughout the metabolic pathways [109].
Perhaps the greatest limitation to biomarker discovery relies on the fact that several
metabolomic studies are essentially descriptive and skip the validation step. Indeed, the
vast majority of the papers just list which metabolites are statistically different between the
groups in study, not proposing candidate biomarkers and/or clearly state the performance
of the proposed metabolites/biomarkers (e.g., AUC, sensitivity, specificity and/or accu-
racy), thus impairing the discussion of which would be the most promising biomar-kers for
PCa. Hence, future studies should be less descriptive and more assertive, propo-sing and
evaluating potential biomarkers. Furthermore, it is also important to include external sets
for model/results validation to improve the robustness of candidate biomarkers and to
include unambiguous biochemical and biological interpretation of PCa metabolic dysregu-
lations. Remarkably, some of the studies included in this revision are already fo-llowing
this direction. In addition, it is well known that especially urinary metabolic profile can
be affected by several factors (e.g., diet, lifestyle, microbiota, race, among others) [107],
so it is also crucial to perform studies in large and more heterogeneous populations (e.g.,
American, African, Caucasian), to ensure that the proposed biomarkers can be applied
among different countries and different lifestyles.
To conclude, metabolomics is a powerful tool to uncover the metabolic signature
of PCa development and progression. The results obtained so far in tissue and urine
metabolomic studies unveiled potential to define new screening/diagnosis biomarkers.
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